x

Table of contents

  • Biosimilars - Emerging Biosimilars - Oncology: Zarxio Launch Tracking (US) Wave 1
    • Key Findings
      • Unaided Awareness of Zarxio Is Low
      • The Majority of Surveyed Oncologists Are Yet to See a Zarxio Medical Representative
      • Who Is the Zarxio Patient?
        • Patient Age
        • Drug Benefit Coverage
        • Primary Treatment
        • Use in G-CSF-Naïve / Currently Treated Patients
      • Who Is the Zarxio Prescriber?
        • Level of Satisfaction with Zarxio
        • Recommendations/Pressure to Use Zarxio
        • Perception of Zarxio's Net Cost
        • Preference for Short-/Long-Acting G-CSF
      • Trends & G-CSF Market
        • Trends Regarding the Uptake of Zarxio
        • Zarxio's Place in the G-CSF Market
      • Zarxio: Differences Between Prescriber and Nonprescriber Profiles
      • Formulary Analysis
        • Reimbursement of G-CSFs
        • Commercial Coverage of G-CSFs in the United States
        • Explanation of Tiers and Restrictions
        • Tier Placement of G-CSFs - Commercial
        • National Tier Placement of G-CSFs by Percentage of Lives: Commercial
        • Tier Placement of G-CSFs - Medicare
        • National Tier Placement of G-CSFs by Percentage of Lives: Medicare
        • Any Formulary Restrictions on G-CSFs
        • Any Formulary Restrictions on G-CSFs: Commercial
        • Any Formulary Restrictions on G-CSFs: Medicare
        • Prior Authorization for G-CSFs
        • Prior Authorization Formulary Restrictions on G-CSFs: Commercial
        • Prior Authorization Formulary Restrictions on G-CSFs: Medicare
        • Quantity Limits on G-CSFs
        • Quantity Limit Formulary Restrictions on G-CSFs: Commercial
        • Quantity Limit Formulary Restrictions on G-CSFs: Medicare
      • Zarxio Awareness and Perceptions
        • Unaided Awareness of Zarxio
          • Unaided Awareness of Biologics Approved for Chemotherapy-Induced Neutropenia
          • Chemotherapy-Induced Neutropenia Biologics Recalled
          • Order Biologics for Chemotherapy-Induced Neutropenia Are Recalled
          • Order of Biologics Recalled for Chemotherapy-Induced Neutropenia
        • Level of Familiarity with Biosimilars and Zarxio
          • Level of Familiarity
        • Physician Perception of Indications in Which Zarxio Was Studied
          • Indications in Which Physicians Believe Zarxio Was Clinically Studied Prior to Approval
        • Physician Perception of Zarxio’s Approved Indications
          • Indications Physicians Believe Zarxio is Approved to Treat
        • Information on Zarxio’s Development
          • Physician Perception of Indications Zarxio Should Be Approved to Treat
            • Indications Physicians Believe Zarxio Should Be Approved to Treat
        • Zarxio Trial and Use
          • Patients Prescribed Zarxio
            • Prescription of Zarxio: Patients Receiving Myelosuppressive Chemotherapy
            • Oncologists Prescribing Zarxio to Cancer Patients Receiving Myelosuppressive Chemotherapy
            • Number of Cancer Patients Receiving Myelosuppressive Chemotherapy Prescribed Zarxio
            • Prescription of Zarxio: Other Hematology-Oncology Patients
            • Hematology-Oncologists Prescribing Zarxio to Patients
            • Number of Hematology-Oncology Patients Prescribed Zarxio
            • Prescription of Zarxio: Any Indication
            • Proportion of Oncologists That Has Prescribed Zarxio to at Least One Patient
            • Healthcare Coverage of Zarxio-Treated Patients
            • Healthcare Coverage for Patients Treated with Zarxio
            • Prevalence of Treatment Switching to Zarxio or Use of Zarxio in Treatment-Naïve Patients
            • Proportion of Zarxio-Treated Patients Who Were G-CSF-Naïve or Switched from Another G-CSF
            • Current and Future Patient Share of G-CSF Products
            • Current and Future Patient Share Assuming Pegfilgrastim Biosimilars Are Not Available
            • Patient Share Expectations Among Zarxio Prescribers and Nonprescribers
            • Current and Future Patient Share of Long- and Short-Acting G-CSFs
          • Prescribers' Experience of Zarxio
            • Reasons for Prescribing Zarxio
            • Reasons for Choosing to Prescribe Zarxio
            • Perceived Similarity Between Zarxio and Neupogen
            • Oncologists' Perception of Zarxio’s Similarity to Neupogen
            • Reported Differences Between Zarxio and Neupogen
            • Satisfaction with Zarxio
            • Overall Level of Satisfaction with Zarxio
            • Perceived Cost of Zarxio
            • Perceived Discount of Zarxio Compared with Neupogen Net Cost
            • Filgrastim Pricing and Medicare Part B Reimbursement
            • Pricing and Medicare Part B Payment Limit/1 mcg of Filgrastim Products
          • Reasons for Not Prescribing Zarxio
            • Oncologists' Reasons for Not Prescribing Zarxio
            • Reasons for Granix Preference
            • Reasons for Oncologists' Preference for Granix over Zarxio
        • External Factors Affecting Zarxio Use
          • Factors That Could Increase Use of Zarxio
          • Factors That Would Encourage Use or Increase Use of Zarxio
          • Sources of Pressure or Recommendations for Use of Zarxio
          • Sources of Pressure for the Use of Zarxio Instead of Other G-CSF Brands
          • Predicted Uptake of Zarxio
          • Predicted Variability in Zarxio Uptake Depending on Patients’ Healthcare Coverage
          • Rate of Acceptance of Zarxio by Patients
          • Percentage of Patients Who Accepted Zarxio When Proposed
          • Opinions on Nonproprietary Names for Biosimilars
          • Oncologists' Opinions on Nonproprietary Names for Biosimilars
        • G-CSF Promotional Activity
          • Most Recent Contact with Medical Representatives
          • Most Recent Contact with Medical Sales Reps for Zarxio and Competitors
          • Topics of Discussion with Medical Representatives
          • Topics Discussed with Medical Representative
        • Future Use of Biosimilars
          • Zarxio's Influence on Willingness to Use Other Biosimilars
            • Likelihood of Prescribing Other Biosimilars: Medical Oncologists
            • Likelihood of Prescribing Other Biosimilars of Oncology Brands as a Result of Zarxio Use
            • Likelihood of Prescribing Other Biosimilars: Hematology-Oncologists
            • Likelihood of Prescribing Biosimilars of Other Products as a Result of Zarxio Use
          • Likelihood of Prescribing Different Filgrastim Biosimilars
          • Likelihood of Prescribing Other Filgrastim Biosimilars
          • Future Patient Share With or Without Pegfilgrastim Biosimilars
          • Future Patient Share if Pegfilgrastim Biosimilars Are Available at a 15-30% Discount to Neulasta
        • Appendix
          • Background on the US G-CSF Market
            • US G-CSF Market Background
            • Short-acting G-CSFs
            • Short-acting G-CSFs
            • Short-Acting G-CSFs US Market Share
            • Long-Acting G-CSFs
            • Approved Long-Acting G-CSFs
            • Long-Acting G-CSF US Market Share
            • G-CSFs Approved in the United States
            • G-CSF Market News
            • Zarxio's Route to the US Market
            • Zarxio's Future Competitive Landscape in the United States
          • Methodology and Objectives
            • Methodology
            • Objectives
            • Significance Testing in This Study
            • Significance Testing in This Study
          • Respondent Demographics
            • Practice Location
            • Practice Location
            • Regional Location of Oncologists
            • Distribution of Oncologists by Region
            • Years in Clinical Practice and Practice Type
            • Years in Clinical Practice
            • Practice Type
            • Patients Under Management: Medical Oncologists
            • Number of Cancer Patients Receiving Myelosuppressive Chemotherapy Managed Per Month
            • Patients Under Management: Hematology-Oncologists
            • Number of Cancer Patients Under Management Per Month
            • Drug Benefit Coverage for Neutropenia Patients
            • Drug Benefit Coverage
            • Drugs Prescribed by Medical Oncologists
            • Drugs Prescribed by Medical Oncologists
            • Drugs Prescribed by Hematology-Oncologists
            • Drugs Prescribed by Hematology-Oncologists

      Author(s): Amy Duval, M Res

      Amy Duval M.Res., is a director in the oncology and biosimilars team at Decision Resources Group. Ms. Duval manages a team of analysts responsible for market research across oncology indications, and also provides client support across Decision Resources Group oncology products.

      Previously, Ms. Duval was a principal analyst in the oncology group, where she developed in-depth expertise in breast and ovarian cancer. Ms. Duval has worked on multiple oncology indications, including malignant melanoma, renal cell carcinoma, and lung cancer, and has worked on topics in both the major and emerging pharmaceutical markets. Ms. Duval earned her B.Sc. in natural sciences and M.Res. in molecular and cellular biology from the University of Birmingham, where she conducted research into the epigenetics of leukemia.


      Related Reports

      Biosimilars - Market Events And Forecast - Oncology

      In 2019, sales of branded monoclonal antibody biologics in oncology exceeded $18 billion across the major markets (United States, EU5, and Jap...

      View Details

      Biomarkers In Oncology - Access & Reimbursement - Detailed, Expanded Analysis (US) Biomarkers In Oncology

      Biomarkers have become an integral component of the treatment landscape for an increasing number of oncology indications. Patients’ biomarker status often directs prescription choice in malig...

      View Details

      Biosimilars - Geographic Focus: China - Biosimilars | China In-Depth | Oncology And Immunology | China

      The approval of Shanghai Henlius Biotech's HLX01—a biosimilar of Roche's Rituxan (rituximab)—in February 2019 marked the beginning of the biosimilars era in China. Since then, b...

      View Details

      Biosimilars - Emerging Biosimilars - Special Topics: Oncology Biosimilars In The United States - Wave 2

      Biosimilars referencing Roche/Genentech’s portfolio of blockbuster oncology monoclonal antibodies—Avastin, Herceptin, and Rituxan—launched in the United States throughout the seco...

      View Details